Roivant Sciences Company Insiders
| ROIV Stock | USD 20.30 0.08 0.40% |
Slightly above 95 percent of Roivant Sciences' insiders are activelly selling. The analysis of the overall insider sentiment regarding Roivant Sciences suggests that a very large number of insiders are panicking. Roivant Sciences employs about 750 people. The company is managed by 23 executives with a total tenure of roughly 1750 years, averaging almost 76.0 years of service per executive, having 32.61 employees per reported executive.
Insider Sentiment 5
Mostly Selling
Selling | Buying |
Latest Trades
| 2025-10-17 | Eric Venker | Disposed 118418 @ 17.06 | View | ||
| 2025-10-16 | Eric Venker | Disposed 318282 @ 17.05 | View | ||
| 2025-10-15 | Eric Venker | Disposed 414683 @ 16.93 | View | ||
| 2025-10-13 | Eric Venker | Disposed 20727 @ 16.25 | View | ||
| 2025-10-09 | Eric Venker | Disposed 104940 @ 16.3 | View | ||
| 2025-10-08 | Eric Venker | Disposed 138602 @ 16.2 | View | ||
| 2025-10-07 | Eric Venker | Disposed 355161 @ 16.15 | View | ||
| 2025-10-06 | Eric Venker | Disposed 171396 @ 16.34 | View | ||
| 2025-09-23 | Eric Venker | Disposed 611000 @ 14.83 | View | ||
| 2025-09-22 | Eric Venker | Disposed 416182 @ 14.99 | View | ||
| 2025-09-19 | Eric Venker | Disposed 683818 @ 14.95 | View | ||
| 2025-09-18 | Matthew Gline | Acquired 3315 @ 15.07 | View | ||
| 2025-09-05 | Vivek Ramaswamy | Disposed 385816 @ 12.96 | View | ||
| 2025-09-04 | Vivek Ramaswamy | Disposed 194933 @ 12.92 | View | ||
| 2025-09-03 | Vivek Ramaswamy | Disposed 1195000 @ 12.5 | View | ||
| 2025-08-20 | Eric Venker | Disposed 100000 @ 11.72 | View | ||
| 2025-07-21 | Eric Venker | Disposed 100000 @ 11.52 | View | ||
| 2025-06-20 | Vivek Ramaswamy | Disposed 577007 @ 11.46 | View | ||
| 2025-06-18 | Vivek Ramaswamy | Disposed 565266 @ 11.45 | View |
Monitoring Roivant Sciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Roivant Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. Roivant Sciences' latest congressional trading
Congressional trading in companies like Roivant Sciences, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Roivant Sciences by those in governmental positions are based on the same information available to the general public.
| 2025-08-13 | Representative Lisa McClain | Acquired Under $15K | Verify |
Roivant Sciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.1243) % which means that it has lost $0.1243 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1736) %, meaning that it created substantial loss on money invested by shareholders. Roivant Sciences' management efficiency ratios could be used to measure how well Roivant Sciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to -0.03 in 2025. Return On Capital Employed is likely to drop to -0.2 in 2025. At this time, Roivant Sciences' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 458.9 M in 2025, whereas Non Currrent Assets Other are likely to drop slightly above 31.8 M in 2025.Common Stock Shares Outstanding is likely to drop to about 710.9 M in 2025. Net Loss is likely to climb to about (862.7 M) in 2025
Roivant Sciences Workforce Comparison
Roivant Sciences is currently regarded as top stock in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 43,808. Roivant Sciences claims roughly 750 in number of employees contributing just under 2% to equities under Health Care industry.
Roivant Sciences Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Roivant Sciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Roivant Sciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Roivant Sciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2025-12-01 | 0.425 | 17 | 40 | 1,845,561 | 9,439,460 |
| 2025-09-01 | 0.8846 | 23 | 26 | 15,992,959 | 5,479,572 |
| 2025-06-01 | 0.275 | 11 | 40 | 2,015,060 | 51,243,627 |
| 2025-03-01 | 0.4333 | 13 | 30 | 15,580,337 | 17,034,180 |
| 2024-12-01 | 0.3871 | 12 | 31 | 2,103,968 | 7,772,813 |
| 2024-09-01 | 0.6765 | 23 | 34 | 38,725,865 | 10,481,120 |
| 2024-06-01 | 0.2917 | 7 | 24 | 577,845 | 41,242,883 |
| 2024-03-01 | 0.2 | 7 | 35 | 1,224,081 | 128,615,479 |
| 2023-12-01 | 0.3448 | 10 | 29 | 1,589,822 | 3,838,106 |
| 2023-09-01 | 0.5217 | 48 | 92 | 2,374,705 | 41,871,998 |
| 2023-06-01 | 0.4615 | 30 | 65 | 3,012,554 | 46,285,932 |
| 2023-03-01 | 0.1333 | 2 | 15 | 4,457 | 16,216,673 |
| 2022-12-01 | 0.129 | 4 | 31 | 4,007,794 | 24,196,828 |
| 2022-09-01 | 1.5556 | 14 | 9 | 995,843 | 117,414 |
| 2022-06-01 | 1.4444 | 13 | 9 | 103,211,074 | 340,550 |
| 2021-12-01 | 0.0189 | 1 | 53 | 313,419 | 85,897,655 |
Roivant Sciences Notable Stakeholders
A Roivant Sciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Roivant Sciences often face trade-offs trying to please all of them. Roivant Sciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Roivant Sciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| MD MBA | President Chair | Profile | |
| PharmD MD | President Immunovant | Profile | |
| Mayukh MD | Chief President | Profile | |
| Amy Mahery | Chief Officer | Profile | |
| Matthew Gline | CEO Director | Profile | |
| Marianne Romeo | Head Management | Profile | |
| Huafeng Xu | Chief Officer | Profile | |
| Jennifer Humes | Chief Officer | Profile | |
| Josh Chen | General Counsel | Profile | |
| Matt Maisak | Chief Platforms | Profile | |
| Vivek Ramaswamy | Founder Chairman | Profile | |
| Alex Gasner | Executive Health | Profile | |
| Jo Chen | General Counsel | Profile | |
| Drew Kramer | Chief Officer | Profile | |
| Kelly Graff | Head People | Profile | |
| Richard Pulik | Chief Officer | Profile | |
| Deya MD | Chief OfficerInResidence | Profile | |
| Ian Rosenblum | Chief Officer | Profile | |
| Srini Ramanathan | Chief Officer | Profile | |
| Rakhi Kumar | Chief Officer | Profile | |
| Josh JD | General Counsel | Profile | |
| Stephanie Griffin | Vice Projects | Profile | |
| David MD | Chief Dermavant | Profile |
About Roivant Sciences Management Performance
The success or failure of an entity such as Roivant Sciences often depends on how effective the management is. Roivant Sciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Roivant management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Roivant management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.03) | (0.03) | |
| Return On Capital Employed | (0.19) | (0.20) | |
| Return On Assets | (0.03) | (0.03) | |
| Return On Equity | (0.04) | (0.04) |
Please note, the imprecision that can be found in Roivant Sciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Roivant Sciences. Check Roivant Sciences' Beneish M Score to see the likelihood of Roivant Sciences' management manipulating its earnings.
Roivant Sciences Workforce Analysis
Traditionally, organizations such as Roivant Sciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Roivant Sciences within its industry.Roivant Sciences Manpower Efficiency
Return on Roivant Sciences Manpower
| Revenue Per Employee | 38.7K | |
| Revenue Per Executive | 1.3M | |
| Net Loss Per Employee | 475.6K | |
| Net Loss Per Executive | 15.5M | |
| Working Capital Per Employee | 6.5M | |
| Working Capital Per Executive | 210.9M |
Additional Tools for Roivant Stock Analysis
When running Roivant Sciences' price analysis, check to measure Roivant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roivant Sciences is operating at the current time. Most of Roivant Sciences' value examination focuses on studying past and present price action to predict the probability of Roivant Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roivant Sciences' price. Additionally, you may evaluate how the addition of Roivant Sciences to your portfolios can decrease your overall portfolio volatility.